

NOVEL APPROACHES IN DEVELOPMENT FOR THE TREATMENT OF PANCREATIC CANCER

James Butera, Martin Malachovsky, Ritesh Rathore, Howard Safran

Departments of Medicine, Brown University, Providence Rhode Island

Received 6/12/98 Accepted 8/6/98

TABLE OF CONTENTS

1. Abstract
2. Farnesyl Transferase Inhibitors
3. Matrix Metalloproteinase Inhibitors
4. Her-2/neu antibodies
5. References

1. ABSTRACT

Pancreatic adenocarcinomas are among the most resistant neoplasms to conventional chemotherapeutics. This has prompted intense investigations of novel non-cytotoxic agents based on new understandings of the molecular pathobiology of human malignancies. This review will focus on the potential uses of three new classes of agents: farnesyl transferase (FPTase) inhibitors, matrix metalloproteinase inhibitors (MMPI's) and antibodies to the HER-2/*neu* oncogene. When used as single agents, FPTase inhibitors and MMPI's may be cytostatic, helping to delay the growth of these cancers. All three classes of agents may have the greatest benefit when used in conjunction with traditional anticancer modalities. The biology of these agents will be reviewed.

2. FARNESYL TRANSFERASE INHIBITORS

FPTase inhibitors were developed following two and one half decades of investigations of the *ras* oncogenes and the proteins they encode. The *ras* genes (Harvey (Ha), Kristen (Ki), and N-*ras*) encode low molecular weight proteins, called Ras (1). Ras, after several post-translational modifications localizes itself to the inner-surface of the plasma membrane (2). In normal cells, Ras proteins cycle between GDP-bound (inactive) and GTP-bound (active) forms to regulate cellular proliferation and differentiation. When certain growth factors bind to their cellular receptors, this causes activation of the GDP-bound Ras protein which exchanges its bound GDP for GTP. This activated form of the Ras protein subsequently triggers a cascade of events which ultimately leads to cell proliferation. The GTPase activity of Ras then turns off the biological event, Ras returns to its inactive form (GDP-bound) and the cycle is thus closed. Ras then remains in an inactive form until a new growth signal arrives (3).

A single point mutation changing an amino acid is responsible for altering the wild-type *ras* gene into an oncogene that efficiently induces neoplastic transformation (1). The mutations in *ras* genes which are frequently found in cancer inhibit the GTPase activity of the Ras protein, thus Ras remains bound to GTP and permanently activated.

This results in the active Ras protein constitutively stimulating cell growth and proliferation (4).

Mutations of the *ras* gene are found in 40% of all cancers and are associated with over 90% of pancreatic

tumors (5). Thus, inhibition of *ras* gene function is a rational target in pancreatic cancer.

Recent progress at blocking Ras-induced cell transforming activity has centered on inhibiting the enzyme farnesyl-protein transferase (6). Membrane localization of Ras is essential for its normal function and the cell transforming activity of its mutated, oncogenic form. Membrane anchoring of Ras is achieved through a series of post-translational modifications. The first and most critical modification is farnesylation of its carboxyl-terminal motif, catalyzed by farnesyl protein transferase (FPTase) (1). Inhibition of the farnesylation reaction by synthetic FPTase inhibitors nullifies Ras membrane anchorage and therefore inhibits Ras protein function as well as its cell transforming capability (4-6).

Enthusiasm grew for a possible Achilles' heel of *ras*-dependent cell transformation when further studies showed that inhibition of FPTase by FPTase inhibitors causes reversal of *ras*-induced transformation of whole cells, inhibition of *ras*-dependent tumor growth in nude mice and causes regression in Ha-*ras* transgenic animals (7-10). Moreover, FPTase inhibitors have not demonstrated toxicity to normal cells in culture or to normal tissues in mice. This observation is in sharp contrast to typical cytotoxic anti-cancer agents which often must be used at their maximally tolerated dose to obtain significant anti-tumor activity.

One of the first objectives in testing FPTase inhibitors was to ensure that these compounds were achieving their therapeutic benefit by inhibiting Ras-mediated signal transduction events and not by another mechanism. In order to accomplish that, FPTase inhibitors were tested on cells transformed by other oncogenes. For instance, FPTase inhibitors should not have the capability of inhibiting *raf* oncogene transformed cells. Indeed, when tested in these cell lines, cells transformed by the *raf* oncogene have been resistant to FPTase inhibitors when used at a similar dose to treat *ras* mediated transformed cells (6). However, recent studies suggest that FPTase inhibitors may also have activity in cell lines that do not have *ras* mutations. This suggests that the exact mechanism of FPTase inhibitors may still be unclear.

It is still not certain whether FPTase inhibitors will have cytostatic or cytotoxic effects. Preclinical models

Novel Therapies for Pancreatic Cancer

suggest that FTPase inhibitors may require chronic administration to be effective, as the tumors would grow back once the drug was discontinued (9). Thus a well tolerated oral formulation would have most promise. Clinical trials will need to be carefully designed to evaluate therapeutic efficacy. For example, while FTPase inhibitors may have little effect as a single agent for patients with metastatic disease it could prevent or delay regrowth of microscopic metastatic deposits in a patient who has undergone surgical resection. Phase I trials of FTPase inhibitors have been initiated.

3. MATRIX METALLOPROTEINASE INHIBITORS

Matrix metalloproteinases (MMP's) are a family of Zn^{2+} dependent endopeptidases with a broad spectrum of proteolytic activity for several components of the extracellular matrix(11). Tumor cells secrete MMP's which destroy basement membranes and local connective tissue, allowing tumor cells to gain access to the lymphatic or blood circulation (12). Once established at a secondary site, tumor cells continues to secrete MMP's that degrade connective tissue enhancing local growth (13). MMP's also appear to promote the growth of new blood vessels that nourish metastatic deposits.

Though MMP's are different in structure, molecular weight and substrate specificity, they all contain highly homologous zinc-binding active sites, hemopexin-like domains, and cleavable NH₂-terminal sequences the removal of which results in activation of the enzymes (14). MMP's are involved not only in pathologic tissue destruction by tumor cells. Their presence was documented during mouse embryogenesis (15). Collagenase activity was reported as important factor during wound healing and tissue remodeling (16). Several matrix metalloproteinases were identified to be secreted by rheumatoid synovial cells and thus contributing to joint destruction in rheumatoid arthritis (17).

In normal human tissues, MMP's are in an inactive proenzyme form and their activity is regulated by its activators and inhibitors (18). A ubiquitous glycoprotein, TIMP, is considered to be a major inhibitor of metalloproteinase activity in tissues. This inhibitor is secreted by many cells in culture including fibroblasts, endothelial cells, chondrocytes and vascular smooth muscle cells. It is also present in bone, cartilage and amniotic fluid. TIMP inhibits MMP by forming irreversible 1:1 stoichiometric complex with the active enzyme (18). During tumor invasion the balance between MMP's and their inhibitors is broken and number of MMP's exceeds TIMP's which contributes to the invasion and degradation of extracellular matrix (19-22).

Early studies on human cancer cell lines and animal models have demonstrated that inhibition of MMP's inhibit the growth and spread of primary tumors and promote the formation of stroma causing encapsulation of the tumor. Some additional beneficial effects on inhibition of angiogenesis were demonstrated as well (23-27).

Many solid tumors, including pancreatic cancer, express high levels of matrix metalloproteinases (28-30). Synthetic inhibitors of MMP's are therefore being

developed to counteract the destructive and invasive nature of these enzymes (31,32).

Marimastat was one of the first MMPI's to show significant oral bio-availability to enter clinical trials. It is a synthetic MMPI that mimics the substrate of the matrix metalloproteinases. This allows it to fit tightly in the active site of the enzyme. Its hydroxamate group binds to the zinc atom in the active site resulting in potent but reversible inhibition of the metalloproteinases MMP-1, MMP-2, MMP-3 and MMP-9.

Initial human trials occurred in normal volunteers, underscoring the fact that marimastat is not a cytotoxic agent. These studies did not indicate untoward toxicity, although some alteration of liver enzymes were noted. Following this, more than 1000 patients with metastatic ovarian, colorectal, pancreatic, prostatic, head and neck, breast, gastric, lung, and melanoma (33-38), have been treated on phase I/II trials to try to identify a biologically effective dose and to further to evaluate the safety profile and pharmacokinetics.

A phase I/II study of marimastat in patients with advanced, non-resectable pancreatic carcinoma has been reported (38). Patients received marimastat on a BID oral schedule for 28 days. One patient developed acute rash, fever, chills and muscle pains after marimastat. Otherwise there have been no significant drug-related toxicities. Seven of 19 patients demonstrated a reduction in the rate of rise of CA 19-9. Marimastat is also being tested by the Brown University Oncology Group in patients with locally advanced pancreatic cancer with stable or responding disease after paclitaxel and radiation. No significant toxicity from marimastat has been seen thus far in this study.

Since marimastat is not a cytotoxic agent, traditional endpoints of objective tumor response are anticipated. The evaluation of disease stabilization in an uncontrolled setting is hard to interpret. Carefully designed phase III trials are needed to determine the effectiveness of marimastat. Therefore a multicenter randomized placebo controlled trial is underway in the United States to evaluate whether marimastat can improve disease free and overall survival in patients with resected pancreatic cancer.

4. HER-2/NEU ANTIBODIES

The HER-2/*neu* proto-oncogene, located at Chromosome 17 p11-q21, encodes for a 185 kd membrane receptor- protein (p185) that shares extensive homology with the epidermal growth factor receptor. Overexpression of HER-2/*neu* is thought to transform cells by constitutively stimulating signal transduction pathways and has been correlated with differentiation, aggressiveness and prognosis in breast, gastric and ovarian carcinomas.

In the pancreas there is increasing data regarding the incidence of HER-2/*neu* overexpression, demonstrated immunohistochemically, with reported figures ranging from 20%- 58 % in invasive ductal adenocarcinomas 39, 40, 41, 42, 43, 44, 45. Overexpression is more common in well and moderately differentiated tumors as compared to poorly differentiated and anaplastic tumors.

Novel Therapies for Pancreatic Cancer

While gene amplification is the predominant pathway of HER-2/*neu* overexpression in most tumors, in pancreatic cancers, increased transcription may play an important role. Elevated mRNA levels of HER-2/*neu* in the absence of gene amplification have been described in pancreatic cancer 39,41, 42, 44.

Herceptin, a human monoclonal antibody to the HER-2/*neu* receptor, has been synthesized by scientists at Genentech. Clinical trials have shown activity in breast carcinomas that overexpress the HER2/*neu* gene. Synergistic activity has been demonstrated in breast cancer with herceptin and paclitaxel. This suggests that studies in other malignancies that overexpress HER2/*neu* such as pancreatic cancer are warranted. The Brown University Oncology Group in collaboration with the M.D. Anderson Cancer Center is therefore initiating a phase II trial of gemcitabine and herceptin as first line therapy for metastatic pancreatic cancer.

5. REFERENCES

1. D.R. Lowy, & B.M. Willumsen: Function and regulation of Ras. *Annu Rev Biochem* 62, 851-91 (1993)
2. A.D. Cox, & C.J. Der: The ras/cholesterol connection: implications for ras oncogenicity. *Crit Rev Oncog* 3, 365-400 (1992)
3. N. E. Kohl, F.R. Wilson, S.C. Mosser, E. Giuliani, S.J. DeSolms, M.W. Conner, N. J. Anthony, W.J. Holtz, R. P. Gomez, T. Lee, R. L. Smith, S.L. Graham, G. D. Hartman, J. B. Gibbs, & A. Oliff: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. *Proc Natl Acad Sci* 91, 9141-9145 (1994)
4. N.E. Kohl, M.W. Conner, J. B. Gibbs, S. L. Graham, G.D. Hartman, & A. Oliff: Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. *J Cell Biochem (supp)* 22, 145-150 (1995)
5. H. Reuveni, A. Gitler, E. Poradosu, C. Gilon, & A. Levitzki: Synthesis and biological activity of semipeptoid farnesyltransferase inhibition. *Bioorg and Med Chem* 5, 85-92 (1997)
6. J. Gibbs, & A. Oliff: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. *Annu Rev Pharmacol Toxicol* 37, 143-66 (1997)
7. E. C. Lerner, Y. Qian, M.A. Blaskovich, R. D. Fossum, A. Vogt, J. Sun, A.D. Cox, C. J. Der, A. D. Hamilton, & S. M. Sebt: Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. *J Bio Chem* 270, 26802-26806 (1995)
8. J. Sun, Y. Qian, A. D. Hamilton, & S. M. Sebt: Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and P53 deletion. *Can Res* 55, 4243-4247 (1995)
9. T. Nagasu, K. Yoshimatsu, C. Rowell, M. D. Lewis, & A. M. Garcia: Inhibition of human tumor xenograft growth by treatment with farnesyl transferase inhibitor B956. *Can Res* 55, 5310-514 (1995)
10. M. A. Hawk, K. T. Cesen, J. C. Siglin, G. D. Stoner, & R. J. Ruch: Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. *Cancer Letters* 109, 217-222 (1996)
11. L.M. Matrisian,: Metalloproteinases and their inhibitors in matrix remodeling. *Trends Genet.*6, 121-125 (1990)
12. L.A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C.M. Foltz & S. Shafie: Metastatic potential correlated with enzymatic degradation of basement membrane collagen. *Nature* 284, 67-68 (1980)
13. I.J. Fiedler & C.L. Balch: The biology of cancer metastasis and implications for therapy. In: M. M. Ravich (ed), *Current Problems in Surgery* 131-209. Chicago: Year Book of Medical Publishers, Inc. (1987)
14. B. Davies, P.D. Brown, N. East, M.J. Crimmin & F.R. Balkwil: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian xenografts. *Cancer Research* 53, 2087-2091, (1993)
15. P. Reponen, C. Shalberg, P. Huhtala, T. Hurskaine, I. Thesleff & K. Tryggvason: Molecular cloning of murine 72k-Da type IV collagenase and its expression during mouse development. *J. Biol. Chem.* 267, 7856-7862, (1992)
16. M.S. Agren, C.J. Taplin, J.F. Woessner, W.H. Eaglestein & P.M. Mertz. Collagenase activity during wound healing. *J. Invest. Dermatol.* 98, 621-621, (1992)
17. Y. Okada, H. Nagase & E.D. & Harris, Jr. Matarix metalloproteinase 1,2, and 3 from rheumatoid synovial cels are sufficient to destroy joints. *J. Rheumatol.* 14, 41-42, (1987)
18. Y.A. DeClerk, N. Perez, H. Shimada, T.C. Boone, K.E. Langley, & S.M. Taylor: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. *Cancer Research* 52, 701-708 (1992)
19. G. Murphy, J.J. Reynolds & R.M. Hembry: Metalloproteinases and cancer invasion and metastasis. *Int. J. Cancer* 44, 757-760, (1989)
20. A. Halaka, R.A. D. Bunning, C.C. Bird, M. Gibson & J.J. Reynolds: Production of collagenase and inhibitor (TIMP) by intracranial tumors and dura in vitro. *J. Neurosurg* 49, 461-466, (1983)
21. N.J. Hicks, R.V. Ward & J.J. Reynolds: A fibrosarcoma model derived from mouse embryo cells: growth properties and secretion of collagenase and metalloproteinase inhibitor (TIMP) by tumor cell lines. *In. J. Cancer* 33, 835-844, (1984)
22. R.E. Hewitt, I.H. Leach, D.G. Powe, I.M. Clark, T.E. Cawston & D.R. Turner: Distribution of collagenase and tissue inhibitor of metalloproteinase (TIMP) in colorectal tumors. *Int. J. Cancer* 49, 666-672, (1991)
23. S. Imren, D.B. Kohn, H. Shimada, L. Blavier, & Y.A. DeClerk: Overexpression of tissue inhibitor of

Novel Therapies for Pancreatic Cancer

metalloproteinases-2 by retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. *Cancer Research* 56, 2891-2895, (1996)

24. A.M.P. Montgomery, B.M. Mueller, R.A. Reisfeld, S.M. Taylor, & Y.A. DeClerk: Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. *Cancer Research* 54, 5467-5473, (1994)

25. B. Davies, P.D. Brown, N. East, M.J. Crimmin, & F.R. Balkwill: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. *Cancer Research* 53, 2087-2091 (1993)

26. B. Himelstein, J. Hua, E. Bernhard, & R.J. Muschel: Importance of MMP-9 expression for metastasis in tumor and tumor stromal cells symposium 7, matrix metalloproteinases and their inhibitors. *Proceedings of the American Association of Cancer Research*, 37, (1996)

27. Y.A. DeClerk & S. Imren: Protease inhibitors, role and potential therapeutic use in human cancer, *Eur J Cancer* 30A, 2170-2180, (1994)

28. U.M. Moll, B. Lane, S. Zucker, K. Suzuki & H. Nagase: Localization of collagenase at the basal plasma membrane of a human pancreatic carcinoma cell line. *Cancer Res* 50, 6995-7002, (1990)

29. X. Lu, M. Levy, I.B. Weinstein & R.M. Santella: Immunological quantitation of levels of tissue inhibitor of MMP-1 in human colon cancer. *Cancer Research* 51, 6231-6235, (1991)

30. C. Monteagudo, J.J. Merino, J. San-Juan, L.A. Liotta & W.G. Stetler-Stevenson: Immunohistochemical distribution of Type IV collagenase in normal benign and malignant breast tissue. *Am J. Pathol.* 136, 585-592, (1991)

31. N.C. Levitt, F. Eskens, D.J. Propper, A.L. Harris, L. Denis, T.S. Ganesan, R.A. Mather, L. McKinley, A. Planting, D.C. Talbot, V. Van Beurden, M. Van der Burg, S. Wilner & J. Verweij: A phase one pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor *Proceedings of ASCO* 17, *823, (1998)

32. L. Grochow, S. O'Reilly, R. Humphrey, P. Sundaresan, R. Donehower, S. Sartorius, J.J. Kennedy, D. Armstrong, M. Carducci, J.M. Soprenson & K. Jumor: Phase one and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPi), Bay 129566. *Proceedings of ASCO* 17, 213a, *822, (1998)

33. P. Boasberg, Harbaugh, M. Eisenberger, J. Harris, A. Laglebe, F. Ahmann, B. Roth, M. Berkheimer, & H. Rasmussen. Marimastat in patients with hormone refractory prostate cancer: a dose-finding study. *Proceedings of ASCO* 16, 316a, (1997)

34. S. Zaknoen, R. Wolff, J. Cox, J. Marshall, T. Bordelon, A. Drumheller & H. Rasmussen.: Marimastat in advanced progressive colorectal cancer - a dose finding study. *Proceedings of ASCO* 16, 273a. (1997)

35. A. Bodurtha, E. Eisenhauer, W. Steward, J. Rusthoven, I. Quirt, R. Lohmann, N. Wainman, & T. Rugg: Phase I-II study of marimastat (BB2516) in patient with metastatic melanoma. *Proceedings of ASCO* 16, 493a (1997)

36. J. Malfetano, N. Teng, J. Barter, A. Lopes, D. Moore, P. Boasberg, & J. Schink, A. Drumheller & H. Rasmussen. *Proceedings of ASCO* 16, 373a, (1997)

37. H. Rasmussen, T. Rugg, P. Brown, M. Baillet & A. Millar. A 371 patient meta-analysis of studies of marimastat in patients with advanced cancer. *Proceedings of ASCO* 16, 429a, (1997)

38. A. Rasemurgy, J. Harris, Langleben A., Casper E, R. Allen & H. Rasmussen. A novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. *Proceedings ASCO* 15, 470, (1996)

39. P.A. Hall, C.M. Hughes, S.L. Staddon, P.I. Richman, W.J. Gullick & N.R. Lemoine. The c-erbB-2 proto-oncogene in human pancreatic cancer. *J Pathol* 161, 195-200, (1990)

40. K. Satoh, H. Sasano, T. Shimosegawa, M. Koizumi, T. Yamazaki, F. Mochizuki, N. Kobayashi, T. Okano, T. Toyota & T. Sawai. An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas. *Cancer* 72, 51-56 (1993)

41. Y. Yamanaka, H. Friess, M.S. Kobrin, M. Buchler, J. Kunz, H.G. Beger & M. Korc. Overexpression of HER-2/neu oncogene in human pancreatic carcinoma. *Hum Pathol*, 24, 1127-1134, (1993)

42. S. Lei, H.E. Appert, B. Nakata, D.R. Domenico, K. Kim, J.M. Howard. Overexpression of HER-2/neu oncogene in pancreatic cancer correlates with shortened survival. *Int J Pancreatol* 17, 15-21, (1995)

43. H. Friess, P. Berberat, M. Schilling, J. Kunz, M. Korc, & M.W. Buchler. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. *J Mol Med*, 74, 35-42 (1996)

44. J.D. Day, J.A. DiGiuseppe, C. Yeo, M. Lai-Goldman, S.M. Anderson, S.N. Goodman, S.E. Kern and R.H. Hruban. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. *Hum Pathol*, 2, 119-124 (1996)

45. M.C. Dugan, S.T. Dergham, R. Kucway, K. Singh, L. Biernat, W. Du, V.K. Vaitkevicius, & F.H. Sarkar. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. *Pancreas*, 14, 229-236 (1997)

Key Words: Pancreatic Cancer, Treatment, Farnesyl Transferase Inhibitors, Matrix Metalloproteinase Inhibitors, Herceptin, Antiangiogenesis Inhibitors

Send correspondence to: Howard Safran, M.D., The Brown University Oncology Group, The Miriam Hospital, 168 Summit Ave, Providence, RI 02908, Tel:(401)-793-7151, Fax: (401)-521-1057, E-mail: hsafran@rihosp.edu